Autologous immune enhancement therapy

NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer

Tuesday, August 13, 2019 - 9:05pm

Stephen Chen, MBA, CTO of NKMax America commented, "Our ability to manufacture and deliver multiple doses of an NK cellular immunotherapy advances us towards our goal of providing a transformative cancer treatment to patients."

Key Points: 
  • Stephen Chen, MBA, CTO of NKMax America commented, "Our ability to manufacture and deliver multiple doses of an NK cellular immunotherapy advances us towards our goal of providing a transformative cancer treatment to patients."
  • The company's SNK product is an autologous therapy manufactured by harvesting a small number of a patient's immune cells.
  • The activated NK cells, known as "SNK" are reinfused in the patient to fight against cancer.
  • Nine subjects will be enrolled in the trial to investigate the safety and tolerability of SNK in adults with pathologically confirmed cancer refractory to conventional therapy.